| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/20-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/5000-1/10000 | Human,Mouse,Rat |
| Aliases | PAN; ADGF; CECR1; IDGFL; SNEDS; VAIHS |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Fusion protein of human ADA2 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于ADA2抗体的3篇代表性文献摘要(注：ADA2相关研究多集中于基因缺陷疾病DADA2.直接针对“ADA2抗体”的研究较少，以下文献涉及相关机制或检测方法)：
---
1. **文献名称**: *Early-onset stroke and vasculopathy associated with mutations in ADA2*
**作者**: Zhou Q. et al.
**摘要**: 本研究首次发现ADA2基因突变导致早发性中风和系统性血管病变(DADA2)，揭示了ADA2在血管内皮功能和免疫调节中的关键作用，但未直接涉及抗ADA2抗体的研究。
---
2. **文献名称**: *Autoantibodies against ADA2 in pediatric-onset polyarteritis nodosa*
**作者**: Navon Elkan P. et al.
**摘要**: 报道在部分儿童结节性多动脉炎患者中发现抗ADA2自身抗体，提示其可能通过抑制ADA2酶活性参与血管炎症的发病机制。
---
3. **文献名称**: *Anti-ADA2 antibodies as a biomarker for monitoring disease activity in DADA2*
**作者**: Lee P.Y. et al.
**摘要**: 提出抗ADA2抗体水平与DADA2患者的疾病活动性相关，可能作为治疗反应和复发的生物标志物，并探讨抗体介导的ADA2功能抑制机制。
---
**备注**：目前研究焦点主要在ADA2基因缺陷(DADA2)而非抗体，若需更针对性文献，建议补充具体研究方向(如自身抗体检测或特定疾病关联)。
The ADA2 antibody is associated with research on adenosine deaminase 2 (ADA2), a protein encoded by the *CECR1* gene. ADA2 functions as an extracellular enzyme involved in purine metabolism, converting adenosine to inosine and regulating extracellular adenosine levels. It plays roles in immune regulation, vascular development, and inflammation. Deficiencies in ADA2 due to genetic mutations cause *DADA2* (Deficiency of ADA2), a rare autosomal recessive disorder characterized by vasculopathy, immune dysregulation, and stroke.
ADA2 antibodies are not inherently pathological but have been studied as tools to detect or inhibit ADA2 activity in research contexts. In autoimmune diseases like VEXAS syndrome or certain vasculitides, autoantibodies targeting ADA2 have been reported, potentially disrupting its anti-inflammatory or vascular-protective functions. These antibodies may contribute to disease mechanisms by altering adenosine signaling or promoting endothelial dysfunction.
Commercial ADA2 antibodies are primarily used in immunoassays (ELISA, Western blot) or immunohistochemistry to quantify protein expression in studies exploring ADA2's role in immune disorders, angiogenesis, or hematopoiesis. Recent research also investigates ADA2 as a biomarker for disease severity in conditions like systemic lupus erythematosus or sepsis. However, the clinical relevance of endogenous ADA2 antibodies remains under investigation, with ongoing studies aiming to clarify their diagnostic or therapeutic potential.
×
